Sepracor Plans Alvesco, Omnaris Drug Launches Following Acquisition From Nycomed
This article was originally published in The Pink Sheet Daily
Executive Summary
Sepracor’s 1,600-person sales force will promote the asthma and allergic rhinitis treatments.